Muscarinic M1 receptor sequence: Preliminary studies on its effects on cognition and expression

Elizabeth Scarr; Suresh Sundram; Azita Deljo; Tiffany Francis Cowie; Andrew Stuart Gibbons; Susan Juzva; Andrew Mackinnon; Stephen J Wood; Renee Testa; Christos Pantelis; Brian Dean

Journal article

Muscarinic M1 receptor sequence: Preliminary studies on its effects on cognition and expression

Elizabeth Scarr, Suresh Sundram, Azita Deljo, Tiffany Francis Cowie, Andrew Stuart Gibbons, Susan Juzva, Andrew Mackinnon, Stephen J Wood, Renee Testa, Christos Pantelis, Brian Dean

SCHIZOPHRENIA RESEARCH | ELSEVIER SCIENCE BV | Published : 2012

DOI: 10.1016/j.schres.2012.02.011

Download PDF

University of Melbourne Researchers

Elizabeth Scarr Author Melbourne Veterinary School

Brian Dean Author Florey Department of Neuroscience and Mental Health

Andrew Gibbons Author Psychiatry

Christos Pantelis Author Psychiatry

Suresh Sundram Author Psychiatry

Related Projects (4)

Defining The Pathology Of A Sub-Type Of Schizophrenia

Schizophrenia is a group of disorders with similar symptoms and no way of distinguishing the different disorders. In our brain collection 25..

Muscarinic Receptors In Mood Disorders

The causes of bipolar disorder and major depressive disorder, which effect many Australians, remain unknown. We have recently shown decrease..

Studies On The Mechanisms By Which Muscarinic Receptors Might Cause Schizophrenia

Schizophrenia is a severe psychiatric disorder that affects approximately 1% of the population. This project will help define changes in the..

Defining The Pathology Of A Sub-Type Of Schizophrenia

Schizophrenia is a group of disorders with similar symptoms and no way of distinguishing the different disorders. In our brain collection 25..

Grants

Awarded by NMHRC

Funding Acknowledgements

Funding for this study was provided by Australian Rotary Health (ES was the ARH Royce Abbey Post-doctoral Fellow) and the NHMRC; CP is an NM&HRC Senior Principal Research Fellow (#628386), BD is an NH&MRC Senior Research Fellow (#APP1002240). This work was supported, in part, by NM&HRC project grants 509333, 628669 and 566967 as well as Operational Infrastructure Support (OIS) from the Victorian State Government. None of the Funding Sources played any role in the study design; collection, analysis or interpretation of data; in the writing of the report; or in the decision to submit the paper for publication.ASG, TFC, SJ, AM, SJW and RT report no competing interests. The following authors have received remuneration in the past: ES received honorarium from AstraZeneca and travel support from GSK. SS has received speakers bureau honoraria, travel funds, advisory panel payments or research grants from AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Janssen-Cilag, Lundbeck, Organon, Pfizer and Sanofi. AK received travel funds. CP has received grant support, travel or consultancy fees from Janssen-Cilag, Eli Lilly, Hospira (Mayne), AstraZeneca, Pfizer and Schering Plough. BD received travel support from GSK, honorarium from Pfizer, Eli Lilly and MSD.Tissues were received from the Victorian Brain Bank Network, which is supported by the Mental Health Research Institute, The Alfred, Victorian Forensic Institute of Medicine, The University of Melbourne and funded by Australia's National Health & Medical Research Council, Helen Macpherson Smith Trust, Parkinson's Victoria and Perpetual Philanthropic Services.